Cytokine release syndrome management sales will expand through 2036, with interleukins (IL-2) holding 42.6% of the cytokine type segment in 2026. The market was valued at USD 26.55 billion in 2025 and is expected to be worth USD 51.45 billion by 2036, creating an incremental opportunity of USD 23.26 billion.